Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Clinical trial NCT06572319 · RECRUITING

Trial details

NCT number: NCT06572319
Sponsor: Zhejiang Cancer Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Gastric Cancer HER2-positive Gastroesophageal Junction Adenocarcinoma

Start date: 2024-09-01
Primary completion: 2026-08-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.